Veridex and LabCorp Agreement Brings CELLSEARCH® CTC Test to China

      Veridex and LabCorp Agreement Brings CELLSEARCH® CTC Test to China

PR Newswire

RARITAN, N.J., Jan. 17, 2013

RARITAN, N.J., Jan. 17, 2013 /PRNewswire/ -- Veridex, LLC today announced an
agreement with LabCorp Clinical Trials that makes the CELLSEARCH^® circulating
tumor cell (CTC) test available for researchers conducting clinical trials in
China. This marks the first clinical reference laboratory in China that
offers CTC testing and comes on the heels of China's State Food & Drug
Administration approval of CELLSEARCH^® as an in vitro diagnostic to manage
patients with metastatic breast cancer.

Under this agreement, LabCorp's Beijing central laboratory will offer CTC
testing on the CELLSEARCH^® platform to customers conducting clinical trials
in China. Drug developers use CTCs in their development programs to perform
"liquid biopsies" and assess the number and nature of CTCs in study
participants' blood streams. An increase or decrease in the number of CTCs
can be an early and strong indicator of a drug's efficacy. The highly
sensitive CELLSEARCH^® test can identify as few as one CTC in a tube of blood,
offering researchers a powerful tool in developing new therapeutic options.

"The value of CTCs as an oncology biomarker is well documented in
peer-reviewed literature," commented Robert McCormack, Ph.D. and Head of
Technology Innovation at Veridex. "As the number of clinical trials in China
continues to rise, drug companies conducting trials there now have another
compelling reason to incorporate CTCs into their protocols. Local testing
will provide faster results for clinical trial investigators."

About Circulating Tumor Cells
Circulating tumor cells are cancer cells that have detached from the tumor and
are found at extremely low levels in the bloodstream. The potential clinical
benefit of capturing and counting CTCs is being investigated as more research
data is gathered about the potential utility of these markers in monitoring
disease progression and potentially guiding personalized cancer therapy.

About the CELLSEARCH^® CTC Test
CELLSEARCH^® is the first and only United States Food & Drug Administration
510(k)-cleared in vitro diagnostic (IVD) test to capture and count CTCs to
determine the prognosis of patients with metastatic breast, colorectal or
prostate cancer. The test can be administered at any time during the course of
therapy as a routine blood test. It is used in combination with other tests
and a clinician's assessment, to provide a more complete picture of a
patient's prognosis.

About Veridex, LLC
Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to
providing physicians with high-value diagnostic oncology products. Veridex IVD
products may significantly benefit patients by helping physicians make more
informed decisions that enable better patient care. Veridex Clinical Research
Solutions provide tools and services that may be used for the selection,
identification and enumeration of targeted rare cells in peripheral blood for
the identification of biomarkers, aiding scientists in their search for new,
targeted therapies. For more information, visit www.veridex.com.

SOURCE Veridex, LLC

Website: http://www.veridex.com
Contact: Kellie McLaughlin, +1-908-927-7477, kmclaugh@its.jnj.com